Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Cancer Med ; 9(3): 1131-1140, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31823521

RESUMEN

Epidermal growth factor receptor (EGFR) is highly expressed in head and neck squamous cell carcinoma (HNSCC) and correlates with poor prognosis. EGFR has been demonstrated to be associated with cancer stem cell traits in HNSCC. However, the underlying molecular mechanism is far from elucidated. Here, SOX2, one of the most important stem cell markers, was identified as a binding partner and substrate of EGFR. EGFR signaling inhibition decreases SOX2 expression by promoting its autophagic degradation. Mechanistically, EGFR activation induces SOX2 phosphorylation at the Y277 site and reduces its ubiquitination, which inhibits its association with p62 and subsequent autophagic degradation. Gefitinib, an EGFR tyrosine kinase inhibitor, shows in vitro and in vivo protective effects against oral cancer cells that can be reversed through autophagy inhibition. Our study suggests that EGFR plays an important role in the development of cancer stem cells by stabilizing SOX2. Targeting EGFR in combination with conventional chemotherapy might be a promising strategy for the treatment of HNSCC through elimination of cancer stem cells.


Asunto(s)
Autofagia/fisiología , Gefitinib/farmacología , Neoplasias de la Boca/patología , Factores de Transcripción SOXB1/metabolismo , Carcinoma de Células Escamosas de Cabeza y Cuello/patología , Animales , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Autofagia/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Receptores ErbB/antagonistas & inhibidores , Receptores ErbB/metabolismo , Gefitinib/uso terapéutico , Humanos , Leupeptinas/farmacología , Macrólidos/farmacología , Masculino , Ratones , Neoplasias de la Boca/tratamiento farmacológico , Mutagénesis , Células Madre Neoplásicas/patología , Inhibidores de Proteínas Quinasas/farmacología , Inhibidores de Proteínas Quinasas/uso terapéutico , Estabilidad Proteica/efectos de los fármacos , Proteolisis/efectos de los fármacos , Factores de Transcripción SOXB1/genética , Carcinoma de Células Escamosas de Cabeza y Cuello/tratamiento farmacológico , Ensayos Antitumor por Modelo de Xenoinjerto
2.
Int J Clin Exp Med ; 8(7): 10459-70, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26379836

RESUMEN

Mesenchymal stem cells (MSCs) are a reliable cell source for tissue regeneration. However, the molecular mechanisms underlying the directed differentiation of MSCs remain unclear; thus, their use is limited. Here, we investigate HOXB7 function in the osteogenic differentiation potentials of MSCs using stem cells from apical papilla (SCAPs) and bone marrow stem cells (BMSCs). The HOXB7 gene is highly expressed in BMSCs compared with dental tissue-derived MSCs. We found that, in vitro, over-expression of HOXB7 in SCAPs enhanced alkaline phosphatase (ALP) activity and mineralization. HOXB7 over-expression affected the mRNA expression of osteonectin (ON), collagen alpha-2(I) chain (COL1A2), bone sialoprotein (BSP), and osteocalcin (OCN), led to the expression of the key transcription factor, runt-related transcription factor 2 (RUNX2), and promoted SCAP osteogenic differentiation in vitro. The knock-down of HOXB7 inhibited ALP activity, mineralization, and the expression of ON, BSP, COL1A2, OCN, and RUNX2 in BMSCs in vitro. In addition, transplant experiments in nude mice confirmed that SCAP osteogenesis was triggered when HOXB7 was activated. Furthermore, Over-expression of HOXB7 significantly increased the levels of HOXB7 associated with the BSP promoter by ChIP assays. Taken together, these results indicate that HOXB7 enhances SCAP osteogenic differentiation by up-regulating RUNX2 and directly activating transcript of BSP. Thus, the activation of HOXB7 signaling might improve tissue regeneration mediated by MSCs. These results provide insight into the mechanism underlying the directed differentiation of MSCs.

3.
Chin J Dent Res ; 14(1): 7-13, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21734941

RESUMEN

Radiation therapy for malignant tumours in the head and neck region are inevitably associated with significant long-term injury to the salivary glands, often resulting in salivary gland hypofunction. The subsequent lack of saliva production leads to many functional and quality-of-life problems for affected patients and there is no effective method to eliminating this problem caused by radiation treatments. Although many studies have been done in animal models, the mechanism of this injury in humans is still unclear. In this review, an animal model (miniature pigs) used in irradiated research is mainly discussed. This review also presents the progress made to date on the gene transfer-mediated functional restoration of irradiated salivary glands and the possibilities provided by future interventions to prevent radiation damage to salivary glands.


Asunto(s)
Acuaporina 1/genética , Técnicas de Transferencia de Gen , Traumatismos Experimentales por Radiación/terapia , Glándulas Salivales/efectos de la radiación , Xerostomía/terapia , Animales , Irradiación Craneana/efectos adversos , Neoplasias de Cabeza y Cuello/radioterapia , Humanos , Proteínas Serina-Treonina Quinasas/genética , Traumatismos Experimentales por Radiación/complicaciones , Traumatismos Experimentales por Radiación/prevención & control , Protectores contra Radiación/uso terapéutico , Glándulas Salivales/lesiones , Porcinos , Porcinos Enanos , Xerostomía/etiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...